Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

Frontiers Recent Discoveries in the Androgen Receptor Pathway in

Cells, Free Full-Text

ASCO GU 2023: Darolutamide plus ADT Versus ADT in Metastatic

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab

Darolutamide and Survival in Metastatic, Hormone-Sensitive

OC Digest 5

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Effect of crossover from placebo to darolutamide on overall

Bayer expands global clinical program for darolutamide in prostate

View of Darolutamide (Nubeqa) Canadian Journal of Health

Patient education: Treatment for advanced prostate cancer (Beyond

Quick Take: Darolutamide in Advanced Prostate Cancer

Cancers, Free Full-Text

PDF) Clinical Development of Darolutamide: A Novel Androgen

Frontiers YIV-818-A: a novel therapeutic agent in prostate